Cardiol Therapeu Stock Price, News & Analysis

Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) has successfully closed its public offering of 8,437,500 Class A common shares at US$1.60 per share, raising gross proceeds of US$13.5 million. The company plans to use the net proceeds to support the clinical development of CardiolRx for treating recurrent pericarditis, as well as for general and administrative expenses, working capital, and other expenses.

Canaccord Genuity acted as the sole bookrunner for the offering. The offering was made pursuant to a U.S. registration statement on Form F-10 and the company's existing Canadian short form base shelf prospectus. A final prospectus supplement was filed with securities commissions in Canada (except Quebec) and the SEC in the United States.

Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) has announced the pricing of its public offering of 8,437,500 Class A common shares at US$1.60 per share, aiming to raise US$13.5 million in gross proceeds. The company plans to use the funds to support the clinical development of CardiolRx for treating recurrent pericarditis, as well as for general expenses and working capital. Canaccord Genuity is acting as the sole bookrunner for the offering, which is expected to close around October 10, 2024. The offering is being made under a U.S. registration statement and Canadian short form base shelf prospectus, with a final prospectus supplement to be filed with relevant securities commissions.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has filed a preliminary prospectus supplement for a proposed public offering of Class A common shares. The supplement was filed with the SEC and SEDAR+ in connection with the company's short form base shelf prospectus. Canaccord Genuity is acting as the sole bookrunner for the offering.

The net proceeds from the offering will be used to support the clinical development of CardiolRx for the treatment of recurrent pericarditis, as well as for general and administrative expenses, working capital, and other expenses. The offering's final terms, including pricing, will be determined in the context of the market. The closing is subject to customary conditions, including listing approvals from the TSX and Nasdaq.

Interested investors can find detailed information about the offering in the supplement and base prospectus available on SEDAR+ and EDGAR.

Cardiol Therapeutics (NASDAQ: CRDL) announced the completion of target patient enrollment for its Phase II ARCHER trial, evaluating CardiolRx™ in acute myocarditis. The trial, with 100 patients from five countries, aims to assess the safety, tolerability, and impact of CardiolRx™ on myocardial recovery. Primary outcomes include measures of left ventricular function and myocardial edema/fibrosis, with topline results expected early next year. This milestone complements data from the MAvERIC Phase II study on recurrent pericarditis, to be presented in November. Acute myocarditis, a severe inflammatory heart disease, lacks FDA-approved therapies, presenting a significant opportunity for Cardiol.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has announced the completion of its MAvERIC Phase II study for recurrent pericarditis. The full clinical data will be presented at the American Heart Association Scientific Sessions 2024 on November 18, 2024. The study investigated the impact of CardiolRx™ on patients with symptomatic recurrent pericarditis. The primary endpoint data showed marked reductions in pericarditis pain and inflammation at 8 weeks. The study involved 27 adult participants across eight U.S. clinical sites and consisted of an 8-week treatment period followed by an 18-week extension period. The presentation will include additional endpoints such as freedom from pericarditis recurrence, 26-week pain scores, inflammatory marker levels, and safety outcomes.

Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) held its annual general and special meeting of shareholders on June 26, 2024. Shareholders voted in favor of all proposed management resolutions. Key resolutions included the re-election of eight directors and the appointment of BDO Canada LLP as auditors. Additionally, the unallocated awards under Cardiol's Omnibus Equity Incentive Plan were approved. The re-elected directors are David Elsley, Peter Pekos, Dr. Guillermo Torre-Amione, Colin Stott, Michael Willner, Jennifer Chao, Chris Waddick, and Teri Loxam. The voting results showed strong support, with directors receiving between 96.01% and 99.66% of the votes cast.

Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) has announced that its Annual General and Special Meeting of Shareholders will be held virtually on June 26, 2024, at 4:30 p.m. EDT. The meeting will be accessible via a live audio webcast at web.lumiagm.com/253136217. During this event, shareholders can participate and vote on various matters. Cardiol is a clinical-stage company dedicated to developing anti-inflammatory and anti-fibrotic therapies for heart disease. Further details on the AGM and participation instructions are available on Cardiol's investor website.

Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRx^TM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension phase. Notably, 80% of patients with elevated CRP levels at baseline showed normalization. The primary endpoint revealed a mean pain reduction of 3.7 on the NRS scale. CardiolRx^TM was well-tolerated and appears promising for future Phase III trials.

Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized.

The ARCHER trial has exceeded 85% of target enrollment, with a target of 100 patients across multiple countries. Its primary measures are cardiac MRI assessments of left ventricular function and myocardial edema/fibrosis. The MAvERIC-Pilot Phase II study for recurrent pericarditis is expected to report topline results in June 2024.

Acute myocarditis is a severe inflammatory condition with significant health risks. Cardiol's CEO highlighted the growing interest in myocarditis treatments and the contributions of clinical collaborators to the study's progress.